Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer-Reference-Cited by-同舟云学术

Rationale for co-targeting IGF-1R and ALK in ALK fusion–positive lung cancer

Published:2014-08-31 Issue:9 Volume:20 Page:1027-1034
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Lovly Christine M,McDonald Nerina T,Chen Heidi,Ortiz-Cuaran Sandra,Heukamp Lukas C,Yan Yingjun,Florin Alexandra,Ozretić Luka,Lim Diana,Wang Lu,Chen Zhao,Chen Xi,Lu Pengcheng,Paik Paul K,Shen Ronglai,Jin Hailing,Buettner Reinhard,Ansén Sascha,Perner Sven,Brockmann Michael,Bos Marc,Wolf Jürgen,Gardizi Masyar,Wright Gavin M,Solomon Benjamin,Russell Prudence A,Rogers Toni-Maree,Suehara Yoshiyuki,Red-Brewer Monica,Tieu Rudy,de Stanchina Elisa,Wang Qingguo,Zhao Zhongming^ORCID,Johnson David H,Horn Leora,Wong Kwok-Kin,Thomas Roman K,Ladanyi Marc,Pao William

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/nm.3667.pdf

Reference32 articles.

1. Grande, E., Bolos, M.V. & Arriola, E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol. Cancer Ther. 10, 569–579 (2011).

2. Camidge, D.R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011–1019 (2012).

3. Katayama, R. et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci. Transl. Med. 4, 120ra117 (2012).

4. Doebele, R.C. et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin. Cancer Res. 18, 1472–1482 (2012).

5. Lovly, C.M. & Pao, W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci. Transl. Med. 4, 120ps122 (2012).

Cited by 242 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance;JTO Clinical and Research Reports;2024-09

2. Targeting ALK receptors in non-small cell lung cancer: what is the road ahead?;Expert Opinion on Therapeutic Targets;2024-08-19

3. Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives;Frontiers in Oncology;2024-07-11

4. ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies;Cancer Drug Resistance;2024-05-23

5. RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report;Heliyon;2024-05